Background Direct oral anticoagulants (DOAC) off-label use data is lacking. Our study aimed
to assess the clinical outcomes in a racially mixed population treated for atrial fibrillation (AF) …

Abstract Background Direct oral anticoagulants (DOACs), namely rivaroxaban, apixaban,
dabigatran, and edoxaban, are now included together with warfarin as standards of care for …

Background The effects of anticoagulants at extremes of body weight (BW) are not well
described. The aim of this study was to analyze the pharmacokinetics/pharmacodynamics …

DOACs begin working faster than warfarin. They also leave the body faster than warfarin.
For example, a DOAC thins the blood and gives full blood clot protection within a few hours …

Highlights•Obesity is an important risk factor for atrial fibrillation.•Despite “obesity paradox”
in atrial fibrillation, patient weight loss preferred.•Oral anticoagulants may be more …

Background Direct oral anticoagulants (DOAC) use remains challenging in obese patients
treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and …

Anticoagulants are frequently used as thromboprophylaxis and in patients with atrial
fibrillation (AF) or venous thromboembolism (VTE). While obesity rates are reaching …

Background Most observational studies on direct oral anticoagulants (DOACs) used single
data sources with limited generalizability. This ARISTOPHANES (Anticoagulants for …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Objective To address common “what if” questions that arise relating to the long-term clinical
follow-up and management of patients receiving the new oral anticoagulants (NOACs) …